Objective: Diagnostic Assessment Reviews are part of the work programme of the National Institute of Health and Care Excellence (NICE) in England to evaluate emergent medical technologies and so ensure timely and consistent adoption within the National Health Service (NHS). New diagnostics have the potential to improve health outcomes and impact positively on health service resource use. This study sought to assess the quality of economic evidence informing Diagnostic Assessment Reviews. Methods: We reviewed 27 Diagnostic Assessment Reviews that had been published by NICE as of 30 May 2017 by summarizing and interpreting the evidence that was used to carry out cost-effectiveness analyses. Common issues and challenges of the assessment process were illustrated. Findings: DARs differed in the methods and assumptions used to construct economic models, and linkage of economic model and diagnostic findings. Even though some diagnostic technologies were estimated to be cost-effective, they were not always adopted for routine use in the NHS. The majority of Diagnostic Assessment Review economic models relied heavily on assumptions and expert opinion, with considerable uncertainty about the cost-effectiveness of diagnostic testing. Conclusions: Diagnostic Assessment Reviews appraisals as commissioned by NICE typically feature varying evidence for diagnostic performance and limited evidence for resource implications and quality of life, often leading to recommendations for further research. Given the process opportunity cost, a two-stage topic selection process, with initial assessment specifying further research and proceeding to full assessment when adequate evidence is available may be more appropriate and help signal to diagnostics companies the type of research evidence required.
Introduction
Diagnostic Assessment Reviews (DARs) are part of the National Institute for Health and Care Excellence (NICE) Diagnostics Assessment Programme (DAP) in England. The DAP seeks to evaluate medical technologies and guide the adoption of clinically worthwhile and cost-effective technologies by the National Health Service (NHS) in England in a timely and consistent manner. Diagnostic technologies include a diverse range of measurements and tests that are used to evaluate patients' conditions. 1 Examples include screening, diagnostic and monitoring tests to rule in or out specific diseases, to assess persistence or progression over time, to guide additional or sequential testing or the adjustment of treatment. [1] [2] [3] To establish the performance of a new diagnostic test reliably, it needs to be compared against an adequate reference standard in a representative population using adequate test accuracy methods. Additionally, while innovative diagnostic technologies may improve health outcomes, they may create a net cost to the health service. Such evidence is pivotal to an adequate assessment of the potential value of any new diagnostic technology.
New, potentially promising, emergent diagnostic technologies are not yet part of routine care, and a poor clinical evidence base presents a common challenge. [1] [2] [3] Long-term data on health and resource impacts may be lacking and may need to be modelled using epidemiological and other data. 1 For this reason, the NICE DAR process typically involves the de novo development of economic models to inform the costeffectiveness analysis. However, while de novo modelling is challenging, it may be the only way to assess uncertainties and may help prioritize future research. The NICE DAR process has been described in detail elsewhere and the key steps involved are shown in Figure 1 . 1 In this paper, we aim to review and assess the quality of economic evidence used in publicly reported DARs as part of NICE's work programme. We highlight some of the common issues and challenges of the DAR assessment process. We conclude with some recommendations about how the DAR Final outcome of the process is the publicaƟon of a DiagnosƟcs Guidance (DG) report process might evolve based on the findings from this review.
Methods
We searched the NICE website on 30 May 2017 for published guidance relating to the DAP and accessed the final Diagnostics Guidance (DG) report for each topic. 4 Our assessment did not include supporting documentation such as External Assessment Group (EAG) reports, model or any addenda. Even though some of this information is publicly available, some of the information is confidential and information on the website is redacted. Therefore, to be consistent across the review process, we only considered the final DG reports using these as the basis for analysis, with the focus on cost-effectiveness evidence and recommendations.
Data were extracted using a bespoke template in Microsoft Excel V R , which included disease area, the technologies and it comparators, stated benefits of the technology, prior cost-effectiveness evidence, type of economic model developed by the EAG, technology costs, key outcomes, modelling methods, key assumptions and limitations, results, conclusions and recommendations by NICE. Data were extracted by one reviewer (HM) and checked by a second reviewer (JM); any disagreements in data extraction were resolved by discussion. Extracted data were synthesized narratively as appropriate.
Quality assessment of diagnostic test accuracy studies can be assessed using the recently published Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA DTA Statement. 5 However, this assessment tool does not consider economic evidence per se. Instead we used the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, the preferred tool to assess the quality of economic evaluation studies. 6 
Findings
As of 30 May 2017, NICE had published 27 DGs. Table 1 presents a summary overview of the main characteristics of each DG. DGs covered a wide range of diseases and disease areas including cancer, circulatory system, musculoskeletal system, liver disease, diarrhoea, allergies, type 1 diabetes, infections, and pre-eclampsia. The stated benefits of technologies considered by DGs included improved imaging; quicker time to test reporting; reduced need for further testing, clinical consultation or hospital visits; and better information for decision making and patient prognosis.
In the following, we present the analysis of the DGs according to six themes: the nature of the comparator used; use of existing evidence of cost-effectiveness; reporting of methods; modelling assumptions; reporting of costs and outcomes; and findings and recommendations.
Nature of the comparators
In most cases, the new technology was compared with either the current technology or current standard clinical assessment, although the numbers of comparator interventions (range: 1-12) and comparator tests (range: 1-4) per appraisal varied. For example, DG11 compared 12 new technologies for addressing irritable bowel disease or irritable bowel syndrome that measured faecal calprotectin levels alongside clinical practice and compared these with clinical practice alone, 7 while DG21 assessed two technologies for managing blood glucose levels in type 1 diabetics with four different comparators (Table 1) . 7 Not all new technologies that were assessed sought to replace existing practice: in eight DGs, the new technologies were intended to augment standard clinical practice. [8] [9] [10] [11] [12] [13] [14] [15] Identifying a suitable comparator was sometimes problematic: DG7 reported that there was no direct comparator for the new technology, 16 while for three DGs there were no direct test data available for some of the new tests. 7, 14, 17 Four DGs reported that the diagnostic technologies could not be compared with each other. 9, 10, 14, 18 Use of existing evidence and models of cost-effectiveness Twenty-one DGs were able to access one or more existing studies with cost-effectiveness evidence (including one abstract 19 and one unpublished study provided by the manufacturer 20 ). There was no relevant costeffectiveness evidence available for two DGs 11, 21 while a further four DGs did not record this information. 16, [22] [23] [24] A total of 18 DGs built de novo economic models [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [19] [20] [21] [22] [24] [25] [26] [27] [28] while 10 DGs developed economic models based on existing previous models. 7, 18, 23, [29] [30] [31] [32] [33] [34] For one DG, a conceptual model was built to explore diagnostic pathways due to the lack of clinical effectiveness data. 15 Reporting of methods used to develop economic models Methods used to construct economic models and link diagnostic findings, clinical and resource data varied between DGs and depended on the available evidence. Relevant methods were not always explicitly reported (Table 2) . For 15 DGs, the evidence for the economic model was derived from a clinical effectiveness review, supplemented by expert opinion. Nine DGs explicitly Currently insufficient evidence to recommend the routine adoption of the tests A conceptual model was developed that showed the data and parameters that are needed As no information, assumptions were needed on: proportion of people needing a particular test; accuracy of diagnostic pathways, treatment decision, probability of allergic reactions, probability of remission and probability of dying 
Modelling assumptions
Reflecting the availability of clinical evidence, various assumptions were required within economic models, with the number of key assumptions being reported for more recent DGs. Key model limitations included: lack of clinical evidence or outcomes to estimate model parameters (17 DGs) [8] [9] [10] [11] [12] [15] [16] [17] [18] [19] 22, 24, 26, 27, [30] [31] [32] ; lack of sensitivity and specificity for the new technologies (explicitly identified in 13 DGs) 8, 11, 13, 14, 16, 17, [20] [21] [22] 24, 26, 29, 33 ; uncertainty about the assumptions that the current practice or technology was an adequate reference standard (10 DGs) 8, 13, 18, 20, 23, [28] [29] [30] 33, 34 ; lack of evidence on quality of life and utilities (8 DGs) 11, 12, 15, 20, 21, 25, 30, 33 ; and lack of clinical evidence to quantify patient benefits or preferences (2 DGs).
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Reporting of cost and outcomes
Technology costs or per patient/sample test costs were reported in 19 DGs, with the most expensive being the new generation cardiac computerized tomography (CT) scanners (approximately £1 million each). 23 Eight DGs did not report technology costs or per patient/sample test costs. 11, 18, 20, 25, 27, 31, 32, 34 The level of disaggregation with which costs were reported for technologies varied between DGs. They could include expected lifetime costs, maintenance, laboratory, disposables and other consumables costs, alongside staff, training, and administration costs. Key clinical outcomes reported included mortality, morbidity, complications or adverse events, test performance and accuracy outcomes. Some DGs reported clinical outcomes used in the model within the cost-effectiveness analysis section, while in some instances clinical outcomes were not described specifically and had to be deduced from the clinical effectiveness review. Seventeen DGs included some sort of disutility value or decrement to utility values in their model. [7] [8] [9] [11] [12] [13] [14] [17] [18] [19] [20] [21] 25, 26, 30, 33, 34 All 27 DGs reported the final outcome for the economic models in terms of quality-adjusted life years. Figure 2 provides an illustration of the overall findings and recommendations issued by reviewed DGs. This highlights that just under half of the DGs (n ¼ 13) found the new technology/ies to be cost-effective (individually or as a class) while only one-third (n ¼ 9) recommended that the technologies be adopted in the NHS, although the nature of the recommendations was mixed. Five DGs found that the new technologies were not cost-effective; of these, one DG recommended the reviewed technology for adoption for one specific group of patients only. 7 Although some technologies were estimated by modelling to be cost-effective, these were not always recommended by the Diagnostic Advisory Committee for routine adoption within the NHS, a finding that does not appear to have changed over time. For example, for DG19, even though the two assessed technologies were estimated to be cost-effective, the Committee stated that there was "currently insufficient evidence to recommend their routine adoption in the NHS". 20 Conversely, the technology assessed in DG21 was not cost-effective, yet it was recommended for adoption in the NHS: the Committee thought the technology would probably be cost-effective when changing some of the model assumptions. 7 Table S1 presents the number of items from each DG fulfilling each recommendation from the CHEERS checklist. Among the 24 recommendations for reporting, eight items were not applicable. All DGs reported the following five items: background and objectives, target population and subgroups, setting and location, comparators, and choice of health outcomes. The other items were not consistently reported. For example, only 10 DGs reported the study perspective and only 13 DGs reported the discount rate for the base-case analyses. The discrepancies may have been due to the DGs not being reported in the traditional format of an economic evaluation.
Findings and recommendations
Quality assessment
Discussion
The NICE DAR programme aims to evaluate emerging diagnostic technologies, using clinical and costeffective evidence, to guide adoption of new technologies within the NHS in England. We have reviewed 27 completed diagnostic guidance reports. Superficially, all 27 DARs to date have reported cost/QALY findings with which to inform NICE decision making, consistent with stated requirements. However, there was considerable heterogeneity in methods, availability and use of evidence, as well as instances of the NICE committee not accepting the (median) findings of costeffectiveness models, mainly due to the insufficient clinical evidence for new technologies.
A limitation of our review was that it was limited to published Diagnostic Guidance (DG), and more information and detail might have been obtained from the EAG reports. We did not include any other information available on the NICE website as this varied between appraisals, mainly in terms of confidential information redacted and we wanted to take a consistent approach in our assessment. However, reliance on expert opinion and assumptions for modelling a pathway of care for diagnostics technologies where there is little evidence available remains a common challenge; in such cases, extensive sensitivity analysis is needed to explore the robustness of such findings. Given the extent of modelling uncertainties, their comprehensive characterization would tend to lead to inconclusive findings.
This review aimed to assess the fitness for purpose of the NICE DARs. This was prompted by our experience of undertaking a review ourselves. 28 It was beyond the scope of this work to formally evaluate experiences in other countries or whether other contexts face similar challenges. However, the diagnostic evidence and extant cost-effectiveness considered within DARs was international and not limited to the English NHS setting. Thus, the challenges experienced by NICE are likely to be found more globally, although different health care systems will place different emphasis on the importance of the clinical evidence in economic evaluation. 35 Diagnostic tests originate from the largest medical device companies to small venture capital start-ups and clinician-driven ventures, with consequent variation in capacity to fund adequate research. It is not clear that the current appraisal process signals to diagnostics companies the type and depth of research required to inform NICE recommendations. Although context specific, it may be helpful for developers of new tests to be more aware of the generic needs of cost-effectiveness models. As a first step, diagnostic accuracy studies should usefully describe the performance and potential of new and existing tests, where an independent reference standard is available. However, these studies often do not capture the comparative costs and outcomes that follow. An adequate test-treat trial, with patients from the relevant population randomized to new and current diagnostic tests, and capturing costs and outcomes (ideally generic quality-of-life) may provide the best evidence. 1 This approach is particularly valuable when identifying an adequate reference standard is problematic. Accurate costing information for new tests should include the full set-up, running and maintenance costs, including staff equipment and site costs and explore plausible volume-of-use and disease prevalence assumptions. Although the mechanism for topic selection used by NICE has been described, it is unclear how it is informed. On the basis of past selection assessed in this review, adequate maturation of evidence does appear influential. While adequate evidence may not guarantee a definitive answer, an immature evidence base is almost certain to yield uncertain findings. Possibly this is a legitimate goal for NICE and 'don't know yet' is a helpful policy outcome. A further complexity for topic selection is the expectation that new diagnostic technologies tend to evolve, create challenges for evidence requirements, the timing of appraisal and subsequent adoption decisions. In this respect, NICE may be 'between a rock and a hard place' with no optimal solution.
The introduction of the DG pathway by NICE was intended as a route for manufacturers to gain rapid and consistent adoption of new diagnostic tests within the NHS. Since the flow of work through the DAR work stream has diminished, there may be a perception from manufacturers that the process is not delivering the hoped-for access. From an academic perspective, the substantial work to construct a cost/QALY model may not be appropriate or efficient given that findings may be dominated by the typical clinical uncertainties we have identified. There are considerable pressures on NICE's capacity to service its expanding programme of evaluation. Consequently, full economic analyses might be better reserved for topics where the weight of clinical evidence passes some threshold. A twostage process might involve an initial assessment of promising technologies, identifying a research pathway where necessary, with final assessment where adequate evidence is available to inform NICE recommendations. Such a process would assess each of the three domains of performance, cost and outcome.
Conclusion
NICE recommendations for adoption of new diagnostic are cautious; of 27 assessments, there were 10 cases of adoption and 9 cases of limited adoption of new diagnostic technologies. The primary issue, given the opportunity cost of the process, is whether these assessments are optimally selected or timed. A two-stage topic selection process, with initial assessment with adequate evidence might help signal to diagnostic companies the type of research evidence required.
